Learn More
OBJECTIVE To compare the 24-month course of health-related quality of life (HRQoL) in patients with long-standing RA treated with a conventional synthetic (cs) or a first, second or third biologic (b) DMARD in daily rheumatological care. METHODS Patients enrolled in the German biologics register RABBIT who were observed over at least 12 months were(More)
OBJECTIVE To compare the approved treatment of rheumatoid arthritis using rituximab + methotrexate (RTX + MTX) versus the off-label treatment variants of RTX in monotherapy or RTX in combination with leflunomide (RTX + LEF). METHODS We included RTX-naive patients enrolled in the German biologics register RABBIT (Rheumatoid Arthritis: Observation of(More)
BACKGROUND The aim was to estimate the impact of individual risk factors and treatment with various disease-modifying antirheumatic drugs (DMARDs) on the incidence of myocardial infarction (MI) in patients with rheumatoid arthritis (RA). METHODS We analysed data from 11,285 patients with RA, enrolled in the prospective cohort study RABBIT, at the start of(More)
BACKGROUND METARTHROS (Metabolic impact on joint and bone disease) is a nationwide German network to investigate the overlap between inflammatory and metabolic diseases. The objective of this study was to compare the body mass index (BMI) distribution in patients with early and established rheumatoid arthritis (RA) with data from the general population, and(More)
  • 1